Cisplatin

DB00515

small molecule approved

Deskripsi

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Struktur Molekul 2D

Berat 300.05
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2. Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.
Volume Distribusi Volume of distribution at steady state = 11-12 L/m^2
Klirens (Clearance) * 15-16 L/h/m^2 [total body clearance, 7-hour infusion of 100 mg/m^2] * 62 mL/min/m^2 [renal clearance, 2-hour infusion of 100 mg/m^2] * 50 mL/min/m^2 [renal clearance, 6- to 7-hour infusion of 100 mg/m^2] The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption.

Absorpsi

Following cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

The parent compound, cisplatin, is excreted in the urine. Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant.

Farmakogenomik

4 Varian
GSTM1 (None)

Patients with this genotype have increased risk of ototoxicity with durg: cisplatin.

LRP2 (None)

Patients with this genotype have increased risk of ototoxicity with durg: cisplatin.

GSTP1 (None)

Patients with this genotype have increased risk of ototoxicity with durg: cisplatin.

XPC (None)

Patients with this genotype have increased risk of ototoxicity with durg: cisplatin.

Interaksi Makanan

1 Data
  • 1. Avoid echinacea. Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.

Interaksi Obat

1480 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cisplatin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cisplatin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cisplatin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cisplatin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Cisplatin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cisplatin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cisplatin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cisplatin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Cisplatin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cisplatin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cisplatin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cisplatin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Cisplatin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Cisplatin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cisplatin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cisplatin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Cisplatin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cisplatin.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Cisplatin.
Cladribine Cisplatin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Cisplatin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Cisplatin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cisplatin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cisplatin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Cisplatin.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Cisplatin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Cisplatin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Cisplatin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Cisplatin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Cisplatin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Cisplatin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cisplatin.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Cisplatin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Cisplatin.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cisplatin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cisplatin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Cisplatin.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Cisplatin.
Oxaliplatin The risk or severity of nephrotoxicity can be increased when Oxaliplatin is combined with Cisplatin.
Vincristine The risk or severity of adverse effects can be increased when Cisplatin is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Cisplatin is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Pentostatin.
Vinblastine The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinblastine.
Linezolid The risk or severity of adverse effects can be increased when Cisplatin is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Imatinib.
Clofarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Clofarabine.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin.
Tretinoin The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Tretinoin.
Irinotecan The risk or severity of adverse effects can be increased when Cisplatin is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Cisplatin is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Cisplatin is combined with Etoposide.
Dacarbazine The risk or severity of adverse effects can be increased when Cisplatin is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Cisplatin is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Cisplatin is combined with Penicillamine.
Sirolimus The risk or severity of adverse effects can be increased when Cisplatin is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Cisplatin is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Cisplatin is combined with Azacitidine.
Dactinomycin The risk or severity of adverse effects can be increased when Cisplatin is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Cisplatin is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Cisplatin is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Cisplatin is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolic acid.
Mercaptopurine The risk or severity of adverse effects can be increased when Cisplatin is combined with Mercaptopurine.
Thalidomide The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Cisplatin.
Melphalan The risk or severity of adverse effects can be increased when Cisplatin is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Cisplatin is combined with Flucytosine.
Procarbazine The risk or severity of adverse effects can be increased when Cisplatin is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Cisplatin is combined with Arsenic trioxide.
Idarubicin The risk or severity of adverse effects can be increased when Cisplatin is combined with Idarubicin.
Estramustine The risk or severity of adverse effects can be increased when Cisplatin is combined with Estramustine.
Mitoxantrone The risk or severity of adverse effects can be increased when Cisplatin is combined with Mitoxantrone.
Lomustine The risk or severity of adverse effects can be increased when Cisplatin is combined with Lomustine.
Paclitaxel The risk or severity of adverse effects can be increased when Cisplatin is combined with Paclitaxel.
Docetaxel The risk or severity of adverse effects can be increased when Cisplatin is combined with Docetaxel.
Dasatinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Dasatinib.
Eculizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Decitabine.
Sunitinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Sunitinib.
Nelarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Nelarabine.
Abatacept The risk or severity of adverse effects can be increased when Cisplatin is combined with Abatacept.
Stepronin The risk or severity of adverse effects can be increased when Cisplatin is combined with Stepronin.
Everolimus The risk or severity of adverse effects can be increased when Cisplatin is combined with Everolimus.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxychloroquine.

Target Protein

DNA
DNA-3-methyladenine glycosylase MPG
Alpha-2-macroglobulin A2M
Serotransferrin TF
Copper transport protein ATOX1 ATOX1

Referensi & Sumber

Synthesis reference: Murray A. Kaplan, Alphonse P. Granatek, "Process for the preparation of microcrystalline cisplatin." U.S. Patent US4322391, issued March 30, 1982.

Contoh Produk & Brand

Produk: 49 • International brands: 4
Produk
  • Cisplatin
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Cisplatin
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Cisplatin
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Cisplatin
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Cisplatin
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Cisplatin
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Cisplatin
    Injection • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Cisplatin
    Injection • 1 mg/1mL • Intravenous • US • Generic • Approved
Menampilkan 8 dari 49 produk.
International Brands
  • Abiplatin
  • Cisplatyl
  • Platidiam
  • Platin — Cadila Healthcare

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul